NASDAQ:GH - Guardant Health Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $136.40
  • Forecasted Upside: 265.98 %
  • Number of Analysts: 12
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 11 Buy Ratings
  • 0 Strong Buy Ratings
$37.27
▼ -0.71 (-1.87%)

This chart shows the closing price for GH by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Guardant Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GH and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GH

Analyst Price Target is $136.40
▲ +265.98% Upside Potential
This price target is based on 12 analysts offering 12 month price targets for Guardant Health in the last 3 months. The average price target is $136.40, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 265.98% upside from the last price of $37.27.

This chart shows the closing price for GH for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 12 polled investment analysts is to buy stock in Guardant Health. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/30/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/28/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/29/2021
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/27/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/25/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/23/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2022
  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/24/2022

Latest Recommendations

  • 0 strong buy ratings
  • 11 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/6/2022CitigroupLower Price Target$120.00 ➝ $100.00High
2/24/2022Canaccord Genuity GroupLower Price TargetBuy$180.00 ➝ $165.00High
2/24/2022Stifel NicolausLower Price TargetBuy$160.00 ➝ $130.00High
2/24/2022CowenLower Price TargetOutperform$170.00 ➝ $110.00High
2/24/2022Canaccord Genuity GroupLower Price TargetBuy ➝ Buy$180.00 ➝ $165.00High
2/24/2022Morgan StanleyLower Price TargetOverweight$125.00 ➝ $120.00High
2/24/2022Wells Fargo & CompanyLower Price TargetOverweight$150.00 ➝ $115.00High
2/24/2022CitigroupLower Price TargetBuy$180.00 ➝ $120.00High
2/24/2022SVB LeerinkLower Price TargetOutperform$170.00 ➝ $140.00High
2/15/2022Morgan StanleyLower Price TargetOverweight$150.00 ➝ $125.00Low
11/5/2021BTIG ResearchReiterated RatingBuy$159.00Low
11/5/2021SVB LeerinkLower Price TargetOutperform$180.00 ➝ $170.00High
6/21/2021Wells Fargo & CompanyBoost Price TargetOverweight$145.00 ➝ $160.00Low
6/15/2021Raymond JamesInitiated CoverageMarket PerformHigh
6/3/2021The Goldman Sachs GroupInitiated CoverageBuy$160.00Low
5/27/2021William BlairReiterated RatingBuyLow
5/25/2021Wells Fargo & CompanyInitiated CoverageOverweight$145.00Low
5/23/2021SVB LeerinkReiterated RatingBuyLow
5/7/2021BTIG ResearchBoost Price TargetBuy$145.00 ➝ $160.00Medium
5/7/2021Morgan StanleyLower Price TargetOverweight$175.00 ➝ $160.00High
2/26/2021Morgan StanleyBoost Price TargetOverweight$130.00 ➝ $175.00Medium
2/25/2021CitigroupBoost Price TargetBuy$155.00 ➝ $190.00High
2/25/2021CowenBoost Price TargetOutperform$140.00 ➝ $190.00High
1/20/2021SVB LeerinkBoost Price TargetOutperform$150.00 ➝ $190.00Medium
1/11/2021Stifel NicolausInitiated CoverageBuy$175.00High
12/17/2020BTIG ResearchBoost Price TargetBuy$132.00 ➝ $145.00High
12/16/2020Smith Barney CitigroupBoost Price Target$145.00 ➝ $155.00Low
12/11/2020SVB LeerinkBoost Price TargetOutperform$130.00 ➝ $150.00High
11/12/2020William BlairReiterated RatingOutperformLow
11/9/2020Morgan StanleyBoost Price TargetOverweight$110.00 ➝ $130.00Medium
11/6/2020JPMorgan Chase & Co.Boost Price TargetOverweight$120.00 ➝ $135.00Medium
9/9/2020Morgan StanleyInitiated CoverageOverweight$110.00High
6/11/2020BTIG ResearchInitiated CoverageBuy$100.00Low
5/8/2020SVB LeerinkReiterated RatingBuy$125.00 ➝ $130.00High
5/8/2020CitigroupBoost Price TargetBuy$100.00 ➝ $110.00High
4/23/2020SVB LeerinkLower Price TargetOutperform$130.00 ➝ $125.00Medium
2/21/2020GuggenheimInitiated CoverageBuy$103.00Medium
1/6/2020CitigroupInitiated CoverageBuy$100.00High
11/8/2019William BlairReiterated RatingOutperformLow
8/7/2019CowenSet Price TargetBuy$110.00High
8/7/2019JPMorgan Chase & Co.Boost Price TargetOverweight$90.00 ➝ $135.00High
5/10/2019JPMorgan Chase & Co.Boost Price TargetOverweight$85.00 ➝ $90.00High
4/10/2019Bank of AmericaUpgradeNeutral ➝ Buy$84.00High
4/3/2019CowenBoost Price TargetOutperform$40.00 ➝ $70.00Low
3/13/2019William BlairReiterated RatingOutperformHigh
3/13/2019JPMorgan Chase & Co.Boost Price TargetOverweight$42.00 ➝ $85.00High
2/28/2019Bank of AmericaReiterated RatingNeutral ➝ Neutral$42.00 ➝ $60.00High
10/29/2018SVB LeerinkReiterated RatingOutperformMedium
10/29/2018CowenInitiated CoverageOutperformHigh
10/29/2018JPMorgan Chase & Co.Initiated CoverageOverweight ➝ Overweight$42.00High
10/29/2018William BlairInitiated CoverageOutperform ➝ OutperformHigh
10/29/2018Bank of AmericaInitiated CoverageNeutral ➝ Neutral$37.00High
(Data available from 5/25/2017 forward)

News Sentiment Rating

-0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
10/27/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
11/26/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
12/26/2021
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 3 very negative mentions
1/25/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/24/2022
  • 2 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
3/26/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
4/25/2022
  • 0 very positive mentions
  • 11 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
5/25/2022

Current Sentiment

  • 0 very positive mentions
  • 11 positive mentions
  • 6 negative mentions
  • 3 very negative mentions
Guardant Health logo
Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.
Read More

Today's Range

Now: $37.27
Low: $36.13
High: $38.10

50 Day Range

MA: $57.57
Low: $28.82
High: $77.35

52 Week Range

Now: $37.27
Low: $27.65
High: $133.82

Volume

1,867,022 shs

Average Volume

1,347,412 shs

Market Capitalization

$3.80 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.7

Frequently Asked Questions

What sell-side analysts currently cover shares of Guardant Health?

The following Wall Street analysts have issued stock ratings on Guardant Health in the last year: BTIG Research, Canaccord Genuity Group Inc., Citigroup Inc., Cowen Inc, Morgan Stanley, Raymond James, Stifel Nicolaus, SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Wells Fargo & Company, William Blair, and Zacks Investment Research.
View the latest analyst ratings for GH.

What is the current price target for Guardant Health?

0 Wall Street analysts have set twelve-month price targets for Guardant Health in the last year. Their average twelve-month price target is $136.40, suggesting a possible upside of 266.0%.
View the latest price targets for GH.

What is the current consensus analyst rating for Guardant Health?

Guardant Health currently has 1 hold rating and 11 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GH will outperform the market and that investors should add to their positions of Guardant Health.
View the latest ratings for GH.

How do I contact Guardant Health's investor relations team?

Guardant Health's physical mailing address is 505 PENOBSCOT DR., REDWOOD CITY CA, 94063. The company's listed phone number is (855) 698-8887 and its investor relations email address is [email protected] The official website for Guardant Health is www.guardanthealth.com. Learn More about contacing Guardant Health investor relations.